Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

IL-33, sST2 e PCR nel Disturbo di Panico

14 novembre 2026 aggiornato da: Mehmet Hamdi ÖRÜM, Elazığ Mental Health and Diseases Hospital

Studio trasversale caso-controllo sull'indagine di IL-33, sST2 e Proteina C-Reattiva nel Disturbo di Panico

Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

This is an observational, cross-sectional, case-control study conducted at the psychiatry outpatient clinic of Elazığ Mental Health and Diseases Hospital. It was planned to include 41 participants in the panic disorder (PD) and 30 healthy controls (HCs) groups. All participants will complete a sociodemographic data form and the DSM-5 Panic Disorder Severity Scale (Adult Form). Venous blood samples will be collected as 5 mL. Serum interleukin-33 (IL-33), soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels will be measured using commercially available ELISA kits. Statistical analyses will include independent samples t-test or Mann-Whitney U test, chi-square test, correlation, regression, and ROC analysis. A p value < 0.05 will be considered statistically significant.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

71

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Elâzığ
      • Elâzığ, Elâzığ, Turchia (Türkiye), 23200
        • Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consisted of adult participants aged 18-65 years. The panic disorder (PD) group included consecutive subjects diagnosed with PD according to DSM-5-TR criteria who were admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. All participants provided informed consent prior to enrollment.

Descrizione

  1. For Panic Disorder (PD) Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
    • Not having previously used any medication for psychiatric purposes (drug-naive)
    • Not having any additional active psychiatric disorders besides PD at the current presentation
    • Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Not having taken any medication or supplements in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For PD Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range

    • Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health

    • Having a history of psychiatric medication use

    • Having an additional psychiatric disorder besides PD at the current application

    • Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study
  2. For Healthy Control Group:

    *Inclusion Criteria:

    • Being between 18-65 years of age

    • Not having any active psychiatric disorder

    • Not having previously used any medication for psychiatric purposes (drug-naive)

    • Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer

    • Not having taken any medication or supplement in the last month
    • Completing sociodemographic and scale data fully
    • Volunteering to participate in the study

    For Healthy Control Group:

    *Exclusion Criteria:

    • Being outside the 18-65 age range
    • Having any active psychiatric disorder
    • Having a history of using psychiatric medication
    • Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
    • Taking any medication or supplement in the last month
    • Incomplete completion of sociodemographic and scale data
    • Not volunteering to participate in the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: CASE_CONTROL
  • Prospettive temporali: CROSS_SECTIONAL

Coorti e interventi

Gruppo / Coorte
Panic Disorder (PD)

Adult participants (18-65 years) diagnosed with panic disorder (PD) according to DSM-5-TR criteria. All of the subjects with PD was drug-naive. Subjects were evaluated at baseline. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters. Clinical assessments in the PD group included the DSM-5 Panic Disorder Severity Scale (Adult Form). Sociodemographic and clinical data were recorded for all participants.

Healthy Control (HC)

Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Interleukin-33 (IL-33)
Lasso di tempo: At hospital admission (baseline)

Interleukin-33 (IL-33) levels measured by ELISA (pg/ml).

At hospital admission (baseline)
Soluble Suppressor Tumorogenicity-2 (sST2)
Lasso di tempo: At hospital admission (baseline)

Soluble Suppressor Tumorogenicity-2 (sST2) levels measured by ELISA (pg/ml)

At hospital admission (baseline)
C-Reactive Protein (CRP)
Lasso di tempo: At hospital admission (baseline)

C-Reactive Protein (CRP) levels measured by ELISA (mg/dL)

At hospital admission (baseline)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Systemic Inflammation Response Index (SIRI)
Lasso di tempo: At hospital admission (baseline)

SIRI was calculated as (neutrophil count × monocyte count)/lymphocyte count. Laboratory staff were blinded to group status.

At hospital admission (baseline)
DSM-5 Panic Disorder Severity Scale-Adult Form (PDS)
Lasso di tempo: At hospital admission (baseline)

The DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) is a 10-item self-assessment scale developed by the American Psychiatric Association (APA) that uses a five-point Likert scale (0=Never; 1=Sometimes; 2=Halfway through; 3=Most of the time; 4=Always). Participants consider how much their panic disorder has affected their personal lives in the past seven days when completing the scale. Scores obtained from the scale items indicate the severity of the panic disorder. The scale can be scored between 0 and 40, with higher scores indicating a more severe panic disorder. The mean total score is calculated by dividing the total raw score by the number of items on the scale.

At hospital admission (baseline)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 luglio 2025

Completamento primario (Effettivo)

5 marzo 2026

Completamento dello studio (Effettivo)

5 marzo 2026

Date di iscrizione allo studio

Primo inviato

25 febbraio 2026

Primo inviato che soddisfa i criteri di controllo qualità

25 febbraio 2026

Primo Inserito (Effettivo)

3 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • EMHDH-2025-2026-PD-IL33-ST2-CR

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Deidentified individual participant data (IPD) underlying the results reported in this study (including demographic variables, serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2) and C-reactive protein (CRP) levels, complete blood count parameters, and DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) will be made available to qualified researchers upon reasonable request for academic purposes. Data will be shared after removal of all direct identifiers and in accordance with applicable ethical approvals and data protection regulations. Access to the data will require a methodologically sound research proposal and a data use agreement. Requests should be directed to the corresponding author.

Periodo di condivisione IPD

Data will be available beginning 6 months after publication and will remain available for 5 years.

Criteri di accesso alla condivisione IPD

Access will be granted to researchers who provide a methodologically sound proposal. Requests must be approved by the principal investigator and may require a data use agreement in accordance with institutional and ethical regulations.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .